Sanofi heads out to surf Belharra in $700M biobucks immunology deal

Sanofi is offering Belharra Therapeutics up to $700 million in biobucks for a tow out to surf the waves of small molecule drug discovery in immunology.

The deal includes $40 million upfront and in near term milestones for Belharra to use its non-covalent chemoproteomics platform to look for new ways to drug targets selected by Sanofi. The remaining cash will be in milestones spread throughout the collaboration, plus royalties.

“By leveraging Belharra’s chemoproteomics platform, we hope to explore immunology targets that, to date, have been considered undruggable,” said Sanofi’s John Bertin, global head of immunology and inflammation research.

Belharra, which launched in January 2023, has built an internal pipeline of therapies in oncology and immunology, however none have been publicly disclosed. The company emerged from stealth with $130 million in capital and a partnership already onboard with Roche’s Genentech. The Swiss pharma pitched in $80 million upfront and put…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks